These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23411345)

  • 1. Cross-talk between EGFR and T-cadherin: EGFR activation promotes T-cadherin localization to intercellular contacts.
    Kyriakakis E; Maslova K; Frachet A; Ferri N; Contini A; Pfaff D; Erne P; Resink TJ; Philippova M
    Cell Signal; 2013 May; 25(5):1044-53. PubMed ID: 23411345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
    Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-Cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma: impact on cell motility.
    Kyriakakis E; Maslova K; Philippova M; Pfaff D; Joshi MB; Buechner SA; Erne P; Resink TJ
    J Invest Dermatol; 2012 Sep; 132(9):2275-85. PubMed ID: 22592160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin.
    Zuo JH; Zhu W; Li MY; Li XH; Yi H; Zeng GQ; Wan XX; He QY; Li JH; Qu JQ; Chen Y; Xiao ZQ
    J Cell Biochem; 2011 Sep; 112(9):2508-17. PubMed ID: 21557297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK/ERK regulates adherens junctions and migration through Rac1.
    Ray RM; Vaidya RJ; Johnson LR
    Cell Motil Cytoskeleton; 2007 Mar; 64(3):143-56. PubMed ID: 17183546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
    Nicholl SM; Roztocil E; Davies MG
    J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y; Li X; Jiang J; Frank SJ
    Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
    Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
    Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation.
    Luwor RB; Chin X; McGeachie AB; Robinson PJ; Zhu HJ
    Growth Factors; 2012 Aug; 30(4):220-9. PubMed ID: 22574813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphatase-mediated crosstalk control of ERK and p38 MAPK signaling in corneal epithelial cells.
    Wang Z; Yang H; Tachado SD; Capó-Aponte JE; Bildin VN; Koziel H; Reinach PS
    Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5267-75. PubMed ID: 17122112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
    Chang CM; Chang PY; Tu MG; Lu CC; Kuo SC; Amagaya S; Lee CY; Jao HY; Chen MY; Yang JS
    Oncol Rep; 2012 Nov; 28(5):1799-807. PubMed ID: 22923287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The P2RY2 Receptor Induces Carcinoma Cell Migration and EMT Through Cross-Talk With Epidermal Growth Factor Receptor.
    Martínez-Ramírez AS; Garay E; García-Carrancá A; Vázquez-Cuevas FG
    J Cell Biochem; 2016 Apr; 117(4):1016-26. PubMed ID: 26443721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of hepatocyte epidermal growth factor receptor mediated activation of mitogen-activated protein kinase signaling pathways in response to growth inhibition by a novel K vitamin.
    Wang Z; Wang M; Carr BI
    J Cell Physiol; 2000 Jun; 183(3):338-46. PubMed ID: 10797308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839).
    Tanno S; Ohsaki Y; Nakanishi K; Toyoshima E; Kikuchi K
    Oncol Rep; 2004 Nov; 12(5):1053-7. PubMed ID: 15492792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
    Albanell J; Codony-Servat J; Rojo F; Del Campo JM; Sauleda S; Anido J; Raspall G; Giralt J; Roselló J; Nicholson RI; Mendelsohn J; Baselga J
    Cancer Res; 2001 Sep; 61(17):6500-10. PubMed ID: 11522647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
    Amin DN; Bielenberg DR; Lifshits E; Heymach JV; Klagsbrun M
    Microvasc Res; 2008 May; 76(1):15-22. PubMed ID: 18440031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cadherin attenuates insulin-dependent signalling, eNOS activation, and angiogenesis in vascular endothelial cells.
    Philippova M; Joshi MB; Pfaff D; Kyriakakis E; Maslova K; Erne P; Resink TJ
    Cardiovasc Res; 2012 Mar; 93(3):498-507. PubMed ID: 22235028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.